STOCK TITAN

PERRIGO COMPANY PLC - PRGO STOCK NEWS

Welcome to our dedicated page for PERRIGO COMPANY PLC news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on PERRIGO COMPANY PLC stock.

Perrigo Company plc (NYSE: PRGO) is a leading global provider of over-the-counter (OTC) consumer goods and pharmaceutical products, delivering high-quality healthcare solutions at affordable prices. Established in 1887, Perrigo has grown from a packager of generic home remedies to a top-five global OTC manufacturer and supplier of store-brand infant formulas. Headquartered in Ireland, Perrigo operates across North America, Europe, Australia, Israel, and China.

Perrigo's diverse product portfolio includes private-label consumer health goods sold to major retailers such as Walmart, Amazon, Costco, and CVS. In addition, the company offers branded OTC products, generic extended topical prescription products, and receives royalties from the multiple sclerosis drug Tysabri®.

In recent years, Perrigo has focused on expanding its consumer self-care business. A significant milestone was the FDA approval of Opill®, the first-ever daily birth control pill available OTC in the U.S., which Perrigo began shipping in March 2024. The company's strategic initiatives also include Project Energize, a growth and efficiency program aimed at driving sustainable, value-accretive growth.

Perrigo continues to make strides in the industry, as evidenced by its financial performance and strategic partnerships. The company reported net sales of $1.1 billion for the first quarter of 2024, despite facing challenges such as inventory de-stocking at U.S. retail customers and supply chain constraints. Perrigo's leadership team, including the recent appointment of Roberto Khoury to lead the Consumer Self-Care International segment, is committed to driving innovation and expanding the company's global footprint.

For more information, visit Perrigo's website.

Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) has appointed Ms. Alison Ives as Executive Vice President and Chief Scientific Officer. Ms. Ives will oversee global research and development and regulatory efforts, joining the Company’s Operating Committee. CEO Murray S. Kessler emphasized her 20 years of experience, highlighting her role in enhancing Perrigo's product portfolio, which now has over $500 million in potential revenue. Ms. Ives expressed confidence in delivering innovation with her team at Perrigo, reinforcing the company's commitment to consumer self-care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
none
-
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) announced that President and CEO Murray S. Kessler and CFO Eduardo Bezerra will engage in investor meetings at the Credit Suisse HALO Investment Summit in New York City on May 25, 2022, with no formal presentation planned.

Kessler is also set to virtually present at the Oppenheimer Consumer Growth and E-Commerce Conference on June 15, 2022, at 9:45 AM EDT. Interested parties can access webcasts via the Perrigo website. Perrigo is a leading provider of consumer self-care products, ranking as the largest store brand OTC player in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
conferences
-
Rhea-AI Summary

Perrigo reported first quarter 2022 net sales of $1.1 billion, reflecting a 6.4% increase from the previous year, with organic growth at 9.7%. The loss per diluted share was $0.01, compared to an earnings per share of $0.02 last year. Adjusted diluted EPS dropped to $0.33 from $0.50, impacted by cost headwinds and foreign exchange fluctuations. The acquisition of HRA Pharma bolstered sales expectations, prompting an increase in fiscal 2022 net sales growth guidance to 8.5%-9.5% from 3.5%-4.5%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) has announced the succession of its executive leadership team. Eduardo Bezerra will become Chief Financial Officer on May 16, 2022, succeeding Ray Silcock, who will retire on July 15, 2022. Todd Kingma, the current EVP and General Counsel, will retire on August 31, 2022, with Kyle Hanson named as his successor, effective June 1, 2022. CEO Murray Kessler emphasized that these appointments are essential to advancing Perrigo's consumer self-care strategy and operational excellence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
-
News
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) declared a quarterly dividend of $0.26 per share, set for payment on June 21, 2022, to shareholders on record as of June 3, 2022. As a prominent global provider of Consumer Self-Care Products, Perrigo continues to lead in the OTC market in the U.S. and ranks among the top players in Europe. This dividend is a demonstration of the company's commitment to returning value to its shareholders and indicates confidence in its ongoing business strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
dividends
-
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) announced the completion of its acquisition of Héra SAS for €1.8 billion (approximately $1.9 billion) in cash on April 29, 2022. This strategic move is intended to enhance Perrigo's position in the consumer self-care market. CEO Murray Kessler highlighted that the acquisition aligns with the company's transformation plan, aiming for improved sales, earnings growth, and margin enhancement. The integration of HRA is set to expand Perrigo's geographic reach and drive innovation in self-care products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) announced that the acquisition of Héra SAS is expected to close on April 29, 2022, pending the satisfaction of remaining conditions in the sale agreement. This acquisition aligns with Perrigo's strategy as a leading provider of self-care products in the OTC market, enhancing its presence in the health and wellness sector. The company asserts its commitment to empowering consumers with affordable self-care solutions, reinforcing its market position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) will announce its first quarter 2022 financial results on May 11, 2022, at 8:30 A.M. (EDT). The conference call will be accessible via webcast on the investor relations section of Perrigo's website. A replay will also be available from 12:00 P.M. (EDT) on May 11 until midnight on May 18, 2022. Perrigo is a significant player in the Consumer Self-Care Products sector, being the largest store brand OTC provider in the U.S. and a top OTC company in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) has successfully closed its senior secured credit facilities totaling $2.6 billion. These facilities include a $1.0 billion revolving credit line and $1.6 billion in term loans. The increased loan size is due to strong market interest. The funds will finance the acquisition of Héra SAS and pay off existing debts, including 4.00% Senior Notes due 2023. The redemption of these notes is set for May 20, 2022. Major banks involved include JPMorgan Chase and Morgan Stanley.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) announced a private offering of $500 million in senior notes due 2030 to finance the acquisition of Héra SAS and refinance existing debt. The offering is expected to close before the acquisition, with cash proceeds placed in escrow until the deal's completion or termination. The notes will be guaranteed by Perrigo and its subsidiaries. Key risks include potential delays in the acquisition and market conditions affecting the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none

FAQ

What is the current stock price of PERRIGO COMPANY PLC (PRGO)?

The current stock price of PERRIGO COMPANY PLC (PRGO) is $26.81 as of November 15, 2024.

What is the market cap of PERRIGO COMPANY PLC (PRGO)?

The market cap of PERRIGO COMPANY PLC (PRGO) is approximately 3.7B.

What products does Perrigo Company plc offer?

Perrigo offers OTC consumer goods, branded OTC products, generic topical prescription products, store-brand infant formulas, and royalties from Tysabri®.

Where is Perrigo Company plc headquartered?

Perrigo Company plc is headquartered in Ireland.

What is Project Energize?

Project Energize is Perrigo's growth and efficiency program aimed at creating sustainable, value-accretive growth by increasing organizational agility and enhancing capabilities.

What is Opill®?

Opill® is the first-ever daily birth control pill available over-the-counter in the U.S., approved by the FDA and launched by Perrigo in 2024.

Who are some of Perrigo's major retail partners?

Perrigo's major retail partners include Walmart, Amazon, Costco, and CVS.

What is Perrigo's focus in the healthcare market?

Perrigo focuses on providing quality affordable healthcare products across various categories and geographies, emphasizing consumer self-care solutions.

What recent changes have occurred in Perrigo's leadership?

Roberto Khoury was recently appointed to lead the Consumer Self-Care International segment, succeeding Svend Andersen who will retire in December 2024.

How did Perrigo perform financially in Q1 2024?

Perrigo reported net sales of $1.1 billion for Q1 2024, facing challenges such as inventory de-stocking at U.S. retail customers and supply chain constraints.

What is Perrigo's approach to innovation?

Perrigo emphasizes innovation through product launches like Opill® and strategic initiatives like Project Energize to drive sustainable growth and enhance consumer well-being.

How can I learn more about Perrigo Company plc?

You can visit Perrigo's website at http://www.perrigo.com for more information on their products, financial performance, and strategic initiatives.

PERRIGO COMPANY PLC

NYSE:PRGO

PRGO Rankings

PRGO Stock Data

3.65B
136.42M
0.32%
97.08%
4.01%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
DUBLIN 2